Notícias e Atividades da Palatin Technologies
Presença
Palatin Technologies é uma empresa listada sob o símbolo PTN (US).
Executivos
Veja o organograma con seus 15 executivos principais
Biografias mais buscadas da Palatin Technologies
- Carl Spana, President, Chief Executive Officer and Director
- John Prendergast, Chairman of the Board
- Anthony Manning, Director
Criar um alerta
para seguir os movimentos de executivos da Palatin Technologies.
Biotecnologia
Palatin Technologies possui 2.349 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).
Popular M&A news in Biotecnologia
- Taiho Pharmaceutical has announced the acquisition of Araris Biotech (publicado em 3 de abril de 2025).
- Maxion Therapeutics acaba de anunciar uma arrecadação de fundos de 72 milhões de dólares. (publicado em 3 de abril de 2025).
- Lantheus Holdings adquiriu Evergreen Theragnostics (publicado em 2 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Palatin Technologies
- Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Palatin Technologies
- Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds | Palatin Technologies
- Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis | Palatin Technologies
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results | Palatin Technologies
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 | Palatin Technologies
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 | Palatin Technologies
- Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity | Palatin Technologies
- Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium | Palatin Technologies
- Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium | Palatin Technologies
- Palatin Receives Notice of Non-Compliance from NYSE American | Palatin Technologies
- View more press releases Close
Redes sociais sobre Palatin Technologies
- Palatin Technologies na Wikipedia, Google News e Yahoo Finance
- Palatin Technologies na LinkedIn, Twitter e YouTube
